Investigation Initiated by Levi & Korsinsky on Agios Pharmaceuticals For Shareholder Violations
On March 11, 2026, Levi & Korsinsky, a prominent law firm known for representing aggrieved shareholders, announced that it has initiated an investigation into Agios Pharmaceuticals, Inc. This comes in light of significant developments surrounding the company's recent clinical trials and the subsequent impact on its stock.
The focal point of this investigation is the topline results released by Agios on November 19, 2025, concerning its Phase 3 trial named RISE UP, which focused on Mitapivat for the treatment of Sickle Cell Disease. While the trial successfully met one of its primary endpoints, the failure to meet the other key endpoint raised serious concerns. Specifically, the trial did not achieve a statistically significant improvement in the annualized rate of pain crises, an essential marker for understanding patient outcomes. Furthermore, the key secondary endpoint related to fatigue, measured through PROMIS Fatigue metrics, was also unmet, which has drawn investor scrutiny.
Following the news of these disappointing results, Agios experienced a notable decline in its stock price, plummeting by $22.33 per share, which left the stock at an opening price of $23.16 per share. Such a significant drop raises questions about the accuracy and completeness of the information disclosed to investors prior to these results. This event has triggered Levi & Korsinsky’s investigation to determine whether investors were misled regarding the viability and effectiveness of Mitapivat, as well as the pharmaceutical company's adherence to federal securities laws.
The law firm is reaching out to investors who suffered financial losses due to this incident, highlighting that they may be entitled to seek legal compensation. Interested parties can access further information through the firm’s website or contact them directly via email or telephone.
Levi & Korsinsky boasts a notable track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past two decades. With a committed team of over 70 legal professionals, the firm specializes in complex securities litigation. Their extensive experience is underscored by being ranked consistently in the Top 50 Report compiled by ISS Securities Class Action Services, attesting to their excellence in representing plaintiff shareholders across the United States.
For those affected by Agios Pharmaceuticals' alleged misrepresentations, Levi & Korsinsky encourages prompt contact to leverage their extensive legal experience. This investigation highlights the ongoing implications of corporate accountability and transparency in the pharmaceutical industry, emphasizing the necessity for companies to provide accurate, comprehensive data to their investors. The outcomes of such investigations can set precedents for future securities cases, affecting how pharmaceutical companies communicate critical results from clinical trials.
As this situation continues to unfold, both current and potential investors are urged to stay informed regarding developments involving Agios Pharmaceuticals to fully understand the risks associated with their investment decisions as this legal inquiry progresses.
The focal point of this investigation is the topline results released by Agios on November 19, 2025, concerning its Phase 3 trial named RISE UP, which focused on Mitapivat for the treatment of Sickle Cell Disease. While the trial successfully met one of its primary endpoints, the failure to meet the other key endpoint raised serious concerns. Specifically, the trial did not achieve a statistically significant improvement in the annualized rate of pain crises, an essential marker for understanding patient outcomes. Furthermore, the key secondary endpoint related to fatigue, measured through PROMIS Fatigue metrics, was also unmet, which has drawn investor scrutiny.
Following the news of these disappointing results, Agios experienced a notable decline in its stock price, plummeting by $22.33 per share, which left the stock at an opening price of $23.16 per share. Such a significant drop raises questions about the accuracy and completeness of the information disclosed to investors prior to these results. This event has triggered Levi & Korsinsky’s investigation to determine whether investors were misled regarding the viability and effectiveness of Mitapivat, as well as the pharmaceutical company's adherence to federal securities laws.
The law firm is reaching out to investors who suffered financial losses due to this incident, highlighting that they may be entitled to seek legal compensation. Interested parties can access further information through the firm’s website or contact them directly via email or telephone.
Levi & Korsinsky boasts a notable track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past two decades. With a committed team of over 70 legal professionals, the firm specializes in complex securities litigation. Their extensive experience is underscored by being ranked consistently in the Top 50 Report compiled by ISS Securities Class Action Services, attesting to their excellence in representing plaintiff shareholders across the United States.
For those affected by Agios Pharmaceuticals' alleged misrepresentations, Levi & Korsinsky encourages prompt contact to leverage their extensive legal experience. This investigation highlights the ongoing implications of corporate accountability and transparency in the pharmaceutical industry, emphasizing the necessity for companies to provide accurate, comprehensive data to their investors. The outcomes of such investigations can set precedents for future securities cases, affecting how pharmaceutical companies communicate critical results from clinical trials.
As this situation continues to unfold, both current and potential investors are urged to stay informed regarding developments involving Agios Pharmaceuticals to fully understand the risks associated with their investment decisions as this legal inquiry progresses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.